Streetbeat News

MRMD

MariMed Inc

Employees

326

Industry

Medicinal and Botanical Manufacturing

Open

0.16

Mkt cap

59M

Volume

18K

High

0.16

P/E Ratio

-5.17

52-wk high

0.39

Low

0.15

Div yield

N/A

52-wk low

0.14

The recent earnings reports from eight major Multi-State Operators (MSOs) in the cannabis industry show mixed results on revenue and EBITDA, but the standout detail is the positive Cash Flow from Operations (CFFO) in Q3. Most companies beat consensus projections for CFFO, with tax deferrals being a significant driver. Investors are advised to focus on CFFO rather than revenue or EBITDA, and to distinguish between repeatable cash flows and future cash outflows due to deferred payments. The Viridian Cannabis Deal Tracker provides insights into capital raise and M&A activity in the cannabis sector.

Portfolio Pulse from Viridian Capital Advisors

November 13, 2023 | 4:47 pm

MariMed Inc. (MRMD) reported Q3 earnings with revenue of $38.8 million, a YoY increase of over 14%. The company's gross profit totaled $16.8 million, up from $16.1 million in the prior year’s period. However, net loss was $4.2 million, compared to the net income of $2.7 million in the prior year’s period. The company's guidance for full-year 2023 includes revenue of $148 million to $150 million and a gross margin of approximately 45%. MariMed’s shares traded 1.5625% lower at $0.315 per share at the time of writing on Thursday morning.

Portfolio Pulse from Jelena Martinovic

November 09, 2023 | 6:49 pm

MariMed reported Q3 losses of $(0.01) per share, a 200% decrease YoY. The company's quarterly sales were $38.80M, missing the analyst consensus estimate of $39.60M by 2.02%. However, this is a 14.41% increase over sales of $33.91M the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 08, 2023 | 10:27 pm

The article lists the marijuana stocks that gained and lost on November 7, 2023. The gainers include Item 9 Labs, Psychemedics, Leafbuyer Techs, Zoned Props, Blueberries Medical, Kaya Holdings, Cansortium, Target Group, CV Sciences, EnWave, Trees, Neptune Wellness Solns, Eastside Distilling, SOL Glb Inv, Cannabix Technologies, and MariMed. The losers include MPX International, EVIO, AusCann Group Holdings, Affinor Growers, Global Compliance, Elixinol Wellness, Body and Mind, 4Front Ventures, Khiron Life Sciences, Cara Therapeutics, GreenGro Technologies, Maple Leaf Green World, RIV Capital, and OrganiGram Holdings.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 9:30 pm

MariMed (OTC:MRMD) is set to release its latest quarterly earnings report on November 8, 2023. Analysts estimate an earnings per share (EPS) of $0.00. The company's past performance shows a mixed impact on the share price post-earnings release. The stock is currently trading at $0.315 and has seen a 37.75% decrease over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 7:02 pm

Zuanic & Associates has initiated coverage on MariMed (OTC:MRMD) with an Overweight rating.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:53 pm

The article lists the marijuana stocks that gained and lost on November 6, 2023. The gainers include 1933 Industries, Psychemedics, OrganiGram Holdings, Leafbuyer Techs, Khiron Life Sciences, BioHarvest Sciences, MariMed, Cannabix Technologies, CLS Holdings USA, and Body and Mind. The losers include Choom Holdings, Australis Capital, EVIO, Rocky Mountain High, Item 9 Labs, Elixinol Wellness, MJ Holdings, Nextleaf Solutions, Cansortium, Blueberries Medical, Trees, iAnthus Capital Hldgs, Zoned Props, 22nd Century Group, Heritage Cannabis Holding, C21 Investments, CV Sciences, Auxly Cannabis Group, GrowGeneration, Kaya Holdings, Canopy Gwth, 4Front Ventures, Neptune Wellness Solns, SOL Glb Inv, Tilray Brands, MedMen Enterprises, SNDL, Emeren Group, and Corbus Pharmaceuticals.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 9:30 pm

Zuanic & Associates initiates coverage of cannabis company MariMed (OTC:MRMD) with an Overweight rating, stating the stock is undervalued compared to its peers. MariMed operates in four states, with significant sales from Illinois, Massachusetts, Maryland, Ohio and upcoming operations in Missouri and Delaware. The company acquired Kind Therapeutics in Maryland in April 2022 and doubled sales with the introduction of recreational cannabis in July 2023. MariMed's FY23 guidance anticipates substantial growth, with sales reaching at least $150 million and an adjusted EBITDA of $32-35 million. The company is expected to become a top 10 multi-state operator by 2025.

Portfolio Pulse from Nicolás Jose Rodriguez

November 05, 2023 | 6:55 pm

On November 3, 2023, several cannabis stocks experienced significant price movements. Notable gainers include EVIO, Choom Holdings, AusCann Group Holdings, Elixinol Wellness, and Nextleaf Solutions. On the other hand, Global Hemp Group, Rocky Mountain High, Rhinomed, Affinor Growers, and Item 9 Labs were among the biggest losers.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 9:30 pm

The cannabis sector experienced significant movement on October 31, 2023. Notable gainers included Choom Holdings, MPX International, and Rocky Mountain High, with shares closing up 9900.00%, 1100.00%, and 100.00% respectively. On the other hand, Global Hemp Group, EVIO, and Target Group were among the biggest losers, with shares closing down 55.11%, 50.00%, and 28.36% respectively.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 9:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.